Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
Saved in:
| Title: | Finerenone in Type 1 Diabetes and Chronic Kidney Disease. |
|---|---|
| Authors: | Heerspink HJL; George Institute for Global Health, University of New South Wales, Sydney.; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Birkenfeld AL; Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany.; German Center for Diabetes Research, Neuherberg, Germany.; Internal Medicine IV, Department of Endocrinology, Diabetology, and Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany., Cherney DZI; Division of Nephrology, University Health Network, Toronto General Hospital, University of Toronto, Toronto., Colhoun HM; Institute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh., Groop PH; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki., Ji L; Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Center, Beijing., Jongs N; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Mathieu C; Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium., Pratley RE; AdventHealth Translational Research Institute, Orlando, FL., Rosas SE; Kidney and Hypertension Unit, Joslin Diabetes Center and Harvard Medical School, Boston., Rossing P; Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen., Skyler JS; Department of Medicine and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami., Tuttle KR; Providence Inland Northwest Health, University of Washington School of Medicine, Spokane., Lawatscheck R; Cardiology and Nephrology Clinical Development, Bayer, Berlin., Brinker M; Cardiology and Nephrology Clinical Development, Bayer, Wuppertal, Germany., Scheerer MF; Medical Affairs and Pharmacovigilance, Pharmaceuticals, TA CardioRenal and Heart Disease, Bayer, Berlin., Russell J; Bayer, Reading, United Kingdom., Schloemer P; Clinical Statistics and Analytics, Bayer, Berlin., McGill JB; Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine in St. Louis, St. Louis. |
| Corporate Authors: | FINE-ONE Investigators |
| Source: | The New England journal of medicine [N Engl J Med] 2026 Mar 05; Vol. 394 (10), pp. 947-957. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41780000 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Finerenone in Type 1 Diabetes and Chronic Kidney Disease. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Heerspink+HJL%22">Heerspink HJL</searchLink>; George Institute for Global Health, University of New South Wales, Sydney.; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Birkenfeld+AL%22">Birkenfeld AL</searchLink>; Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany.; German Center for Diabetes Research, Neuherberg, Germany.; Internal Medicine IV, Department of Endocrinology, Diabetology, and Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Cherney+DZI%22">Cherney DZI</searchLink>; Division of Nephrology, University Health Network, Toronto General Hospital, University of Toronto, Toronto.<br /><searchLink fieldCode="AU" term="%22Colhoun+HM%22">Colhoun HM</searchLink>; Institute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh.<br /><searchLink fieldCode="AU" term="%22Groop+PH%22">Groop PH</searchLink>; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki.<br /><searchLink fieldCode="AU" term="%22Ji+L%22">Ji L</searchLink>; Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Center, Beijing.<br /><searchLink fieldCode="AU" term="%22Jongs+N%22">Jongs N</searchLink>; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Mathieu+C%22">Mathieu C</searchLink>; Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Pratley+RE%22">Pratley RE</searchLink>; AdventHealth Translational Research Institute, Orlando, FL.<br /><searchLink fieldCode="AU" term="%22Rosas+SE%22">Rosas SE</searchLink>; Kidney and Hypertension Unit, Joslin Diabetes Center and Harvard Medical School, Boston.<br /><searchLink fieldCode="AU" term="%22Rossing+P%22">Rossing P</searchLink>; Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen.<br /><searchLink fieldCode="AU" term="%22Skyler+JS%22">Skyler JS</searchLink>; Department of Medicine and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami.<br /><searchLink fieldCode="AU" term="%22Tuttle+KR%22">Tuttle KR</searchLink>; Providence Inland Northwest Health, University of Washington School of Medicine, Spokane.<br /><searchLink fieldCode="AU" term="%22Lawatscheck+R%22">Lawatscheck R</searchLink>; Cardiology and Nephrology Clinical Development, Bayer, Berlin.<br /><searchLink fieldCode="AU" term="%22Brinker+M%22">Brinker M</searchLink>; Cardiology and Nephrology Clinical Development, Bayer, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22Scheerer+MF%22">Scheerer MF</searchLink>; Medical Affairs and Pharmacovigilance, Pharmaceuticals, TA CardioRenal and Heart Disease, Bayer, Berlin.<br /><searchLink fieldCode="AU" term="%22Russell+J%22">Russell J</searchLink>; Bayer, Reading, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Schloemer+P%22">Schloemer P</searchLink>; Clinical Statistics and Analytics, Bayer, Berlin.<br /><searchLink fieldCode="AU" term="%22McGill+JB%22">McGill JB</searchLink>; Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine in St. Louis, St. Louis. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22FINE-ONE+Investigators%22">FINE-ONE Investigators</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220255562%22">The New England journal of medicine</searchLink> [N Engl J Med] 2026 Mar 05; Vol. 394 (10), pp. 947-957. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Massachusetts+Medical+Society%22">Massachusetts Medical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0255562 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1533-4406 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200284793%22">00284793 </searchLink><i>NLM ISO Abbreviation: </i>N Engl J Med <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41780000 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1056/NEJMoa2512854 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 947 Titles: – TitleFull: Finerenone in Type 1 Diabetes and Chronic Kidney Disease. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Heerspink HJL – PersonEntity: Name: NameFull: Birkenfeld AL – PersonEntity: Name: NameFull: Cherney DZI – PersonEntity: Name: NameFull: Colhoun HM – PersonEntity: Name: NameFull: Groop PH – PersonEntity: Name: NameFull: Ji L – PersonEntity: Name: NameFull: Jongs N – PersonEntity: Name: NameFull: Mathieu C – PersonEntity: Name: NameFull: Pratley RE – PersonEntity: Name: NameFull: Rosas SE – PersonEntity: Name: NameFull: Rossing P – PersonEntity: Name: NameFull: Skyler JS – PersonEntity: Name: NameFull: Tuttle KR – PersonEntity: Name: NameFull: Lawatscheck R – PersonEntity: Name: NameFull: Brinker M – PersonEntity: Name: NameFull: Scheerer MF – PersonEntity: Name: NameFull: Russell J – PersonEntity: Name: NameFull: Schloemer P – PersonEntity: Name: NameFull: McGill JB IsPartOfRelationships: – BibEntity: Dates: – D: 05 M: 03 Text: 2026 Mar 05 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1533-4406 Numbering: – Type: volume Value: 394 – Type: issue Value: 10 Titles: – TitleFull: The New England journal of medicine Type: main |
| ResultId | 1 |